THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC.
Among the studies published, four studies on the Idylla™ GeneFusion Assay highlighted the strengths of Idylla™ testing including high accuracy, ease-of-use and rapid time-to-results.
Furthermore, one study performed with the new SeptiCyte RAPID® EDTA blood-compatible cartridges4 on the Idylla™ platform, developed in collaboration with Immunexpress, concluded that the addition of the widely used EDTA blood tube as a validated sample type has the potential to greatly enhance the clinical utility of this new near-patient sepsis diagnostic.
The other studies related to the use of the Idylla™ EGFR Assay, the Idylla™ MSI Assay, and the Idylla™ NRAS-BRAF Assay.
These studies highlight the benefit of Idylla™ testing versus more complex and time-consuming technologies. With Idylla™, the time-to-result of diagnostic testing is decreased, indicating the suitability of Idylla™ testing for rapid molecular testing.
|
Page |
Abstract ID |
Title |
|
53 |
ID007 |
Multi-Site Validation of EDTA Blood as a Sample Type for SeptiCyte RAPID CE-IVD, a Near-Patient Diagnostic Test for Sepsis on the Biocartis Idylla System |
|
79 |
I012 |
Evaluation of RET Fusion Identification by the Idylla GeneFusion Assay |
|
90 |
ST006 |
Clinical Validation of an Automated Gene Fusion Assay for Non-Small Cell Lung Carcinoma |
|
90 |
ST008 |
Development and Validation of an Ultra-Rapid Assay for Detection of NTRK1/2/3 Fusions |
|
92 |
ST013 |
Validation of Idylla EGFR Assay for Rapid Detection of EGFR Mutations in Patients’ FFPE Tissues |
|
94 |
ST016 |
Performance of MSI Testing by the Automated Rapid Idylla Assay in Comparison with the Promega Assay in MMR-Deficient Endometrial Carcinomas |
|
95 |
ST019 |
BioCartis Idylla Testing for EGFR Mutations in Lung Adenocarcinoma Reveals Low Clinical Sensitivity for Detecting Exon 20 Insertion Alterations |
|
100 |
ST034 |
Rapid Assessment of Kinase Gene Fusions Using the Idylla GeneFusion Assay in Lung Adenocarcinoma |
|
103 |
ST041 |
Idylla BRAF and NRAS |
Check regulatory status in your country
